Literature DB >> 6872622

Intracranial ependymomas in childhood. Survival and functional results of 47 cases.

A Pierre-Kahn, J F Hirsch, F X Roux, D Renier, C Sainte-Rose.   

Abstract

A pediatric series of 47 intracranial ependymomas (15 supra- and 32 infratentorial) is presented. All children were operated upon between 1969 and 1979. Among these children, 35 completed the treatment with radiotherapy. The irradiation was usually limited to the intracranial content but in 7 patients, it was extended to the spinal axis as well. Malignant ependymomas represented 69% of the whole series (86% of the supratentorial and 53% of the infratentorial ependymomas). The operative mortality rate was 17%. The 5-year survival rate was 39% in the whole series and 51% when excluding postoperative mortality. Recurrences developed in 41% of cases and metastases in 20%. The study of this series and of the literature points out that: (1) metastases from supratentorial ependymomas are not frequent, almost always supratentorial and secondary to a malignant ependymoma, and (2) metastases from infratentorial ependymomas are almost always intraspinal and occur in one third of these tumors. The rate of seeding is especially high in the case of malignant infratentorial ependymomas (50%) but is also 15% in the case of benign tumors. These data lead the authors to propose a craniospinal irradiation in the case of infratentorial ependymomas whether benign or malignant, an irradiation of only the brain in the case of malignant supratentorial ependymoma, an irradiation of only the tumoral bed when ependymomas are benign and supratentorial.

Entities:  

Mesh:

Year:  1983        PMID: 6872622     DOI: 10.1159/000120108

Source DB:  PubMed          Journal:  Childs Brain        ISSN: 0302-2803


  27 in total

1.  Prognostic relevance of localization and grading in intracranial ependymomas of childhood.

Authors:  R I Ernestus; R Schröder; H Stützer; N Klug
Journal:  Childs Nerv Syst       Date:  1996-09       Impact factor: 1.475

2.  Fourth ventricle ependymomas. A study of 20 cases with survival analysis.

Authors:  L Ferrante; L Mastronardi; G Schettini; P Lunardi; A Fortuna
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

3.  Intracranial ependymomas in children.

Authors:  S Undjian; M Marinov
Journal:  Childs Nerv Syst       Date:  1990-05       Impact factor: 1.475

4.  Supratentorial ependymomas in childhood: clinicopathological findings and prognosis.

Authors:  R I Ernestus; O Wilcke; R Schröder
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

5.  Interstitial irradiation of a large, low grade ependymoma with stereotactically implanted iodine-125 seeds. Case report.

Authors:  J Voges; C Gaus; W Schlegel; O Pastyr; B Wowra; V Sturm
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

6.  Expression of estramustine-binding protein in ependymomas and in human and developing rat ependymal cells.

Authors:  A T Bergenheim; M Hartman; J Bergh; P A Ridderheim; R Henriksson
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

7.  Brain tumours in children. A plea for an interdisciplinary working group.

Authors:  F J Schulte; H D Herrmann
Journal:  Acta Neurochir (Wien)       Date:  1988       Impact factor: 2.216

Review 8.  The impact of technical adjuncts in the surgical management of cerebral hemispheric low-grade gliomas of childhood.

Authors:  M S Berger
Journal:  J Neurooncol       Date:  1996 May-Jun       Impact factor: 4.130

9.  Outcomes of malignant CNS ependymomas: an examination of 2408 cases through the Surveillance, Epidemiology, and End Results (SEER) database (1973-2005).

Authors:  Dayron Rodríguez; Michael C Cheung; Nadine Housri; Alfredo Quinones-Hinojosa; Kevin Camphausen; Leonidas G Koniaris
Journal:  J Surg Res       Date:  2009-05-14       Impact factor: 2.192

10.  The history of ependymoma management.

Authors:  Kyu-Won Shim; Dong-Seok Kim; Joong-Uhn Choi
Journal:  Childs Nerv Syst       Date:  2009-05-21       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.